-- 
Israeli Stocks: Biondvax, NetVision, Perrigo, Strauss Group

-- B y   S u s a n   L e r n e r   a n d   C l a u d i a   M a e d l e r
-- 
2011-06-16T15:11:25Z

-- http://www.bloomberg.com/news/2011-06-16/israeli-stocks-biondvax-netvision-perrigo-strauss-group.html
Israel ’s TA-25 Index advanced the
most this month, climbing 1.4 percent to 1,205.59 at the 4:30
p.m. close in  Tel Aviv . The gauge dropped 1.1 percent this week.
Investors traded about 2.4 billion shekels ($692 million) in
shares and convertible securities.  The following stocks rose or fell. Symbols are in
parentheses.  Biondvax Pharmaceuticals Ltd. (BNDX)   climbed 3.7
percent, the biggest gain since June 1, to 2.123 shekels. The
maker of flu vaccines said a so-called Phase IIa clinical trial
of its universal  flu vaccine  successfully met targets.  NetVision Ltd. (NTSN)   rose 0.9 percent to 47 shekels,
the highest close since May 31.  Cellcom Israel Ltd. (CEL)  
agreed to buy the communication services provider for 1.54
billion shekels ($441 million). Cellcom gained 1.9 percent to
99.61 shekels.  Redhill Biopharma Ltd. (RDHL IT) gained 1.8 percent to
2.949 shekels, the highest close since June 13. The manufacturer
of pharmaceuticals signed agreements for two clinical trials of
its RHB-104 treatment for Crohn’s disease to be conducted in
Europe and the U.S.  Perrigo Co. (PRGO)   climbed the most in more than a
month, gaining 2.9 percent to 291.3 shekels. The maker of over-
the-counter drugs said its partner  Teva Pharmaceutical
Industries Ltd. (TEVA)   started shipping a generic version of
Sanofi’s Nasacort AQ nasal spray to treat allergies. Teva, the
world’s largest maker of generic drugs, rose 2 percent to 170.6
shekels.  Strauss Group Ltd. (STRS)  , a maker of dairy products,
slid 1.7 percent to 50.88 shekels, the lowest close in more than
a year. Interior Minister Eli Yishai asked the attorney general
to open an investigation into a possible price-fixing of the
milk market.  To contact the reporters on this story:
 Susan Lerner  in Jerusalem at 
 slerner2@bloomberg.net ;
Claudia Maedler in Dubai at 
 cmaedler@bloomberg.net   To contact the editor responsible for this story: 